Capricor Therapeutics Inc (NASDAQ:CAPR) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 150,000 shares, an increase of 158.2% from the August 30th total of 58,100 shares. Currently, 5.7% of the company’s shares are sold short. Based on an average trading volume of 864,800 shares, the days-to-cover ratio is presently 0.2 days.
CAPR opened at $2.50 on Friday. Capricor Therapeutics has a 12 month low of $2.30 and a 12 month high of $11.50. The business has a fifty day moving average price of $2.81 and a 200 day moving average price of $2.34.
Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.59) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.21. Capricor Therapeutics had a negative return on equity of 270.78% and a negative net margin of 794.63%. The firm had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $0.22 million. As a group, research analysts forecast that Capricor Therapeutics will post -2.87 EPS for the current fiscal year.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.